Cheryn Song

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3268593/publications.pdf Version: 2024-02-01

	331259	395343
1,606	21	33
citations	h-index	g-index
		0007
111	111	2307
docs citations	times ranked	citing authors
	citations 111	1,60621citationsh-index111111

CHERVN SONC

#	Article	IF	CITATIONS
1	Association Between Sarcopenia and Survival of Patients with Organ-Confined Renal Cell Carcinoma after Radical Nephrectomy. Annals of Surgical Oncology, 2022, 29, 2473-2479.	0.7	12
2	ASO Author Reflections: Muscle Mass Matters Even Among the Surgically Fit Patients with Early Renal Cancer. Annals of Surgical Oncology, 2022, 29, 2480-2481.	0.7	0
3	ASO Author Reflections: Papaverine and Beneficial Renal Effects in Robot-Assisted Partial Nephrectomy. Annals of Surgical Oncology, 2022, , 1.	0.7	0
4	Effect of Papaverine on Renal Artery Blood Flow during Robot-Assisted Partial Nephrectomy: A Randomized Controlled Study. Annals of Surgical Oncology, 2022, , 1.	0.7	1
5	ASO Visual Abstract: Effect of Papaverine on Renal Artery Blood Flow During Robot-Assisted Partial Nephrectomy. Annals of Surgical Oncology, 2022, , 1.	0.7	0
6	A Machine Learning Approach to Predict the Probability of Brain Metastasis in Renal Cell Carcinoma Patients. Applied Sciences (Switzerland), 2022, 12, 6174.	1.3	3
7	Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome. Journal of Surgical Oncology, 2021, 123, 204-213.	0.8	18
8	Differential contribution of the factors determining long-term renal function after partial nephrectomy over time. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 196.e15-196.e20.	0.8	6
9	Targeted therapy response in early versus late recurrence of renal cell carcinoma after surgical treatment: A propensity scoreâ€matched study using the Korean Renal Cancer Study Group database. International Journal of Urology, 2021, 28, 417-423.	0.5	3
10	Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma. Medicine (United States), 2021, 100, e26826.	0.4	2
11	ASO Visual Abstract: Association Between Sarcopenia and the Survival of Patients with Organ-Confined Renal Cell Carcinoma After Radical Nephrectomy. Annals of Surgical Oncology, 2021, , 1.	0.7	1
12	Risk Factors Leading to Radical Cystectomy in Patients Who Had Undergone Nephroureterectomy. The Korean Journal of Urological Oncology, 2021, 19, 271-280.	0.1	0
13	Utility of Urinalysis as a Follow-up Surveillance Tool in Nonmuscle Invasive Bladder Cancer. The Korean Journal of Urological Oncology, 2021, 19, 244-251.	0.1	0
14	Construction of a Retrospective Cohort to Observe 10-Year Urologic Cancer Treatment Trends at the Biggest Medical Center of South Korea. The Korean Journal of Urological Oncology, 2021, 19, 232-243.	0.1	1
15	Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?. Clinical Genitourinary Cancer, 2020, 18, 50-55.	0.9	5
16	Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis. Journal of Cancer, 2020, 11, 7202-7208.	1.2	3
17	Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 537-543.	1.2	6
18	The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma. Scientific Reports, 2020, 10, 6967.	1.6	3

#	Article	IF	CITATIONS
19	Surgical details and renal function change after robotâ€assisted partial nephrectomy. International Journal of Urology, 2020, 27, 457-462.	0.5	6
20	Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database. Investigative and Clinical Urology, 2020, 61, 260.	1.0	5
21	The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma. Investigative and Clinical Urology, 2020, 61, 475.	1.0	7
22	Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2293-2301.	1.2	12
23	Integrity of the Urethral Sphincter Complex, Nerve-sparing, and Long-term Continence Status after Robotic-assisted Radical Prostatectomy. European Urology Focus, 2019, 5, 823-830.	1.6	33
24	Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette–Guérin immunotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2131-2140.	1.2	5
25	Adjuvant chemotherapy versus observation after radical cystectomy in patients with node-positive bladder cancer. Scientific Reports, 2019, 9, 8305.	1.6	10
26	Survival and clinical prognostic factors in metastatic nonâ€clear cell renal cell carcinoma treated with targeted therapy: A multiâ€institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. Cancer Medicine, 2019, 8, 3401-3410.	1.3	13
27	Robotâ€assisted partial nephrectomy is associated with early recovery of renal function: Comparison of open, laparoscopic, and robotâ€assisted partial nephrectomy using DTPA renal scintigraphy. Journal of Surgical Oncology, 2019, 119, 1016-1023.	0.8	15
28	Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e420-e428.	0.9	6
29	Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry. Cancer Research and Treatment, 2019, 51, 758-768.	1.3	9
30	Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study. BMC Cancer, 2018, 18, 271.	1.1	3
31	Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib. Journal of Korean Medical Science, 2018, 33, e325.	1.1	13
32	Does epithelioid angiomyolipoma have poorer prognosis, compared with classic angiomyolipoma?. Investigative and Clinical Urology, 2018, 59, 357.	1.0	16
33	Prognostic Factors Related to Recurrence-Free Survival for Primary Carcinoma in situ of the Bladder after Bacillus Calmette-Guérin: A Retrospective Study. Urologia Internationalis, 2018, 101, 269-276.	0.6	11
34	Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy. Journal of Urology, 2018, 200, 989-995.	0.2	16
35	Association between serum levels of insulinâ€like growth factorâ€1, bioavailable testosterone, and pathologic Gleason score. Cancer Medicine, 2018, 7, 4170-4180.	1.3	5
36	Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical recurrence in men with organ confined prostate cancer. BMC Urology, 2018, 18, 7.	0.6	5

#	Article	IF	CITATIONS
37	Declining incidence of benign lesions among small renal masses treated with surgery: Effect of diagnostic tests for characterization. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 362.e9-362.e15.	0.8	11
38	Comprehensive genetic characterization of TFE3-positive renal cell carcinoma Journal of Clinical Oncology, 2018, 36, 635-635.	0.8	0
39	Comparison of Hand-Assisted Laparoscopic <i>vs</i> Robot-Assisted Laparoscopic <i>vs</i> Open Partial Nephrectomy in Patients with T1 Renal Masses. Journal of Endourology, 2017, 31, 374-379.	1.1	16
40	Surgical treatment of renal cell carcinoma: Can morphological features of inferior vena cava tumor thrombus on computed tomography or magnetic resonance imaging be a prognostic factor?. International Journal of Urology, 2017, 24, 102-109.	0.5	11
41	Obesity as a Risk Factor for Unfavorable Disease in Men with Low Risk Prostate Cancer and its Relationship with Anatomical Location of Tumor. Journal of Urology, 2017, 198, 71-78.	0.2	10
42	Does Ureteral Catheter Insertion Decrease the Risk of Urinary Leakage After Partial Nephrectomy in Patients With Renal Cell Carcinoma?. Clinical Genitourinary Cancer, 2017, 15, e707-e712.	0.9	5
43	Adaptive functional change of the contralateral kidney after partial nephrectomy. American Journal of Physiology - Renal Physiology, 2017, 313, F192-F198.	1.3	6
44	Fate of newly developed pulmonary embolism after surgery for renal cell carcinoma with vena cava thrombus. International Urology and Nephrology, 2017, 49, 1157-1163.	0.6	10
45	Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 717-723.	0.9	31
46	Prognostic heterogeneity in T3aN0M0 renal cell carcinoma according to the site of invasion. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 458.e17-458.e22.	0.8	24
47	Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1845-1851.	1.2	27
48	Heterogeneous oncologic outcomes according to surgical pathology in high-risk prostate cancer: implications for better risk stratification and preoperative prediction of oncologic outcomes. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1871-1878.	1.2	1
49	Clinicopathologic Characteristics and Prognosis of Xp11.2 Translocation Renal Cell Carcinoma: Multicenter, Propensity Score Matching Analysis. Clinical Genitourinary Cancer, 2017, 15, e819-e825.	0.9	14
50	Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2017, 79, 173-180.	1.1	1
51	Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor- β (PDGF- β), and PDGF- β receptor expression in papillary renal cell carcinoma. Human Pathology, 2017, 61, 78-89.	1.1	5
52	Prognostic Significance of Macroscopic Appearance in Clear Cell Renal Cell Carcinoma and Its Metastasisâ€Predicting Model. Pathology International, 2017, 67, 610-619.	0.6	5
53	Risk of Intravesical Recurrence After Ureteroscopic Biopsy for Upper Tract Urothelial Carcinoma: Does the Location Matter?. Journal of Endourology, 2017, 31, 259-265.	1.1	31
54	Preserving Renal Function through Partial Nephrectomy Depends on Tumor Complexity in T1b Renal Tumors. Journal of Korean Medical Science, 2017, 32, 495.	1.1	7

#	Article	IF	CITATIONS
55	Renal cell carcinoma in endâ€stage renal disease: Multiâ€institutional comparative analysis of survival. International Journal of Urology, 2016, 23, 465-471.	0.5	10
56	Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1651-1657.	1.2	20
57	Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2331-2338.	1.2	31
58	Characteristics of Anteriorly Located Prostate Cancer and the Usefulness of Multiparametric Magnetic Resonance Imaging for Diagnosis. Journal of Urology, 2016, 196, 367-373.	0.2	25
59	Effect of preoperative urodynamic detrusor overactivity on post-prostatectomy incontinence: a systematic review and meta-analysis. International Urology and Nephrology, 2016, 48, 53-63.	0.6	6
60	Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 339-347.	1.1	4
61	Percutaneous Kidney Biopsy for a Small Renal Mass: A Critical Appraisal of Results. Journal of Urology, 2016, 195, 568-573.	0.2	64
62	Comparative analysis of oncologic outcomes for open vs. robot-assisted radical prostatectomy in high-risk prostate cancer. Korean Journal of Urology, 2015, 56, 572.	1.2	17
63	Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Japanese Journal of Clinical Oncology, 2015, 45, 96-102.	0.6	34
64	Clinicopathological features of Xp11.2 translocation renal cell carcinoma. Korean Journal of Urology, 2015, 56, 212.	1.2	10
65	The Therapeutic Effect of Solifenacin Succinate on the Recovery From Voiding Dysfunction After Radical Prostatectomy in Men With Clinically Localized Prostate Cancer: A Prospective, Randomized, Controlled Study. Urology, 2015, 85, 1123-1129.	0.5	17
66	Prevalence of High-grade or Insignificant Prostate Cancer in Korean Men With Prostate-specific Antigen Levels of 3.0-4.0Âng/mL. Urology, 2015, 85, 610-615.	0.5	6
67	Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor. Cancer Chemotherapy and Pharmacology, 2015, 75, 1025-1035.	1.1	6
68	Hilar Location is an Independent Prognostic Factor for Recurrence in T1 Renal Cell Carcinoma After Nephrectomy. Annals of Surgical Oncology, 2015, 22, 344-350.	0.7	21
69	Prognostic significance of platelet-derived growth factor receptor-Î ² expression in localized clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2213-2220.	1.2	15
70	Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer. Prostate, 2015, 75, 211-217.	1.2	22
71	Clinicohistological characteristics of renal cell carcinoma in children: A multicentre study. Canadian Urological Association Journal, 2015, 9, 705.	0.3	7
72	Prognostic biomarker exploration for patients with metastatic renal cell carcinoma receiving VEGFR TKI Journal of Clinical Oncology, 2015, 33, 491-491.	0.8	0

#	Article	IF	CITATIONS
73	Clinical outcome of patients with metastatic renal cell carcinoma who interrupted VEGFR-TKI after achieving stable disease or better response Journal of Clinical Oncology, 2015, 33, 459-459.	0.8	0
74	Risk of Chronic Kidney Disease After Nephrectomy for Renal Cell Carcinoma. Korean Journal of Urology, 2014, 55, 636.	1.2	11
75	The Type of Nephrectomy Has Little Effect on Overall Survival or Cardiac Events in Patients of 70 Years and Older With Localized Clinical T1 Stage Renal Masses. Korean Journal of Urology, 2014, 55, 446.	1.2	12
76	Predictors of Unfavorable Disease after Radical Prostatectomy in Patients at Low Risk by D'Amico Criteria: Role of Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2014, 192, 402-408.	0.2	23
77	Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway. Prostate, 2014, 74, 1240-1248.	1.2	22
78	Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor. Cancer Research and Treatment, 2014, 46, 339-347.	1.3	5
79	Changes of pulmonary function test and development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus Journal of Clinical Oncology, 2014, 32, 530-530.	0.8	Ο
80	Active surveillance as a treatment option for metastatic or recurrent renal cell carcinoma Journal of Clinical Oncology, 2014, 32, 426-426.	0.8	0
81	VEGF/VEGFR2 and PDGF-B/PDGFR-Î ² expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients. International Journal of Clinical and Experimental Pathology, 2014, 7, 7681-9.	0.5	13
82	Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus. Anticancer Research, 2014, 34, 5723-8.	0.5	3
83	Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component. Journal of Cancer Research and Clinical Oncology, 2013, 139, 817-827.	1.2	19
84	Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 168-174.	0.8	26
85	Preoperative Factors Predictive of Posterolateral Extracapsular Extension After Radical Prostatectomy. Korean Journal of Urology, 2013, 54, 824.	1.2	14
86	Percent tumor volume predicts biochemical recurrence after radical prostatectomy: multi-institutional data analysis. International Journal of Clinical Oncology, 2012, 17, 355-360.	1.0	20
87	Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. Journal of Cancer Research and Clinical Oncology, 2012, 138, 687-693.	1.2	22
88	Followup of Unilateral Renal Function After Laparoscopic Partial Nephrectomy. Journal of Urology, 2011, 186, 53-58.	0.2	40
89	Renal Function Change After Refluxing Type Orthotopic Ileal Substitution. Journal of Urology, 2011, 186, 1948-1952.	0.2	11
90	Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation. BJU International, 2010, 106, 188-193.	1.3	19

#	Article	IF	CITATIONS
91	Urodynamic interpretation of changing bladder function and voiding pattern after radical prostatectomy: a longâ€term followâ€up. BJU International, 2010, 106, 681-686.	1.3	56
92	Solitary Fibrous Tumor of the Kidney - A Report of Two Cases with Review of Literature Korean Journal of Pathology, 2010, 44, 420.	1.2	2
93	Management of Urethral Fistulas and Strictures after Hypospadias Repair. Korean Journal of Urology, 2009, 50, 46.	0.2	4
94	Predictive Factors for Upgrading or Upstaging in Biopsy Gleason Score 6 Prostate Cancer. Korean Journal of Urology, 2009, 50, 836.	1.2	5
95	Differential Diagnosis of Complex Cystic Renal Mass Using Multiphase Computerized Tomography. Journal of Urology, 2009, 181, 2446-2450.	0.2	46
96	Factors Influencing Renal Function Reduction After Partial Nephrectomy. Journal of Urology, 2009, 181, 48-54.	0.2	125
97	Identification of the optimal time to treat urgency after a midurethral sling procedure for stress urinary incontinence. International Urogynecology Journal, 2008, 19, 573-576.	0.7	9
98	Mass Screening for Prostate Cancer in Korea: A Population Based Study. Journal of Urology, 2008, 180, 1949-1953.	0.2	17
99	Relationship Between the Integrity of the Pelvic Floor Muscles and Early Recovery of Continence After Radical Prostatectomy. Journal of Urology, 2007, 178, 208-211.	0.2	94
100	Clinico-pathological Characteristics of Prostate Cancer in Korean Men and Nomograms for the Prediction of the Pathological Stage of the Clinically Localized Prostate Cancer: A Multi-institutional Update. Korean Journal of Urology, 2007, 48, 125.	0.2	12
101	Continuing Trends of the Clinical Parameter Migration in Patients with Prostate Cancer in Korea. Korean Journal of Urology, 2007, 48, 574.	0.2	9
102	The Effectiveness of Simultaneous Renal Artery-vein Clamping during Laparoscopic Partial Nephrectomy on the Surgical Outcome. Korean Journal of Urology, 2007, 48, 897.	0.2	5
103	Impact of Vesico-ureteral Reflux on Renal Function after a Radical Cystectomy: a Comparison of Refluxing and Antirefluxing Orthotopic Bladder Substitutes. Korean Journal of Urology, 2007, 48, 933.	0.2	1
104	The change in renal function in the supranormal hydronephrotic kidney after pyeloplasty. BJU International, 2007, 99, 1483-1486.	1.3	10
105	Transforming growth factor-β downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2007, 133, 487-492.	1.2	6
106	Changes in the Upper Urinary Tract After Radical Cystectomy and Urinary Diversion: A Comparison of Antirefluxing and Refluxing Orthotopic Bladder Substitutes and the Ileal Conduit. Journal of Urology, 2006, 175, 185-189.	0.2	25
107	Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology, 2006, 68, 820-824.	0.5	68
108	Effects of Bladder Training and/or Tolterodine in Female Patients with Overactive Bladder Syndrome: A Prospective, Randomized Study. Journal of Korean Medical Science, 2006, 21, 1060.	1.1	44

#	Article	IF	CITATIONS
109	The Anatomic Distribution and Pathological Characteristics of Prostate Cancer: A Mapping Analysis. Korean Journal of Urology, 2006, 47, 578.	0.2	5
110	Nomograms for the Prediction of Pathologic Stage of Clinically Localized Prostate Cancer in Korean Men. Journal of Korean Medical Science, 2005, 20, 262.	1.1	19